eResearchTechnology (eRT), a provider of centralized ECG and eClinical technology, ePRO and other services to the biotech, pharmaceutical and medical device industries, appointed Keith Schneck as executive vice president and chief financial officer.

Schneck joins eRT with more than 30 years of senior financial experience and executive management expertise in high growth companies and public accounting.

He was previously executive vice president and chief financial officer of Neoware, a publicly traded company before its acquisition in September 2007 by computer giant Hewlett-Packard.

eResearchTechnology had 2007 revenue of $87 million.

In other Personnel moves in the clinical research industry:

Perceptive Informatics, the technology subsidiary of contract research organization Parexel, appointed Kenneth G. Faulkner, Ph.D., to the position of vice president of Medical Imaging. Faulkner, who has 22 years of experience in the application of specialized medical imaging techniques in support of biopharmaceutical product development, will oversee medical imaging worldwide.

"Biopharmaceutical companies are increasingly using our novel medical imaging analyses as biomarkers or surrogate endpoints to assess safety and efficacy. Dr. Faulkner's in-depth experience will further strengthen Perceptive Informatics' medical imaging capabilities to help clients accelerate decisions about the development of new treatments," said Todd A. Joron, corporate vice president and general manager of Perceptive Informatics.

Prior to joining Parexel, Faulkner was vice president of Scientific Services at Synarc, a provider of centralized imaging, molecular markers, and clinical research facilities, which he helped to found in 1998.  Faulkner added, "Perceptive Informatics is a clear leader in the field of medical imaging in support of clinical research, especially through the combination of its in-depth therapeutic expertise and advanced imaging technologies.”

Perceptive Informatics’ medical imaging division provides specialized services for clinical study sponsors who increasingly rely on medical imaging as a surrogate endpoint in assessing the efficacy and safety of new products.